Pepcid, Pepcid AC
Classifications: antisecretory agent (h2-receptor antagonist); Therapeutic: antiulcer; h2-receptor antagonist
Pregnancy Category: B
10 mg, 20 mg, 40 mg tablets; 40 mg/5 mL suspension; 10 mg/mL, 20 mg/50 mL injection
A potent competitive inhibitor of histamine at histamine (H2) receptor sites in gastric parietal cells. Inhibits basal, nocturnal, meal-stimulated, and pentagastrin-stimulated gastric
secretion; also inhibits pepsin secretion.
Reduces parietal cell output of hydrochloric acid; thus, detrimental effects of acid on gastric mucosa are diminished.
Short-term treatment of active duodenal ulcer. Maintenance therapy for duodenal ulcer patients on reduced dosage after healing
of an active ulcer. Treatment of pathologic hypersecretory conditions (e.g., Zollinger-Ellison syndrome), benign gastric ulcer,
gastroesophageal reflux disease (GERD), gastritis.
Stress ulcer prophylaxis.
Hypersensitivity to famotidine or other H2-receptor antagonists; sudden GI bleeding; lactation.
Renal insufficiency; renal failure; PKU; hepatic disease; elderly; pregnancy (category B).
Route & Dosage
Adult: PO 40 mg h.s. or 20 mg b.i.d. PO Maintenance Therapy 20 mg h.s. IV 20 mg q12h
Child: PO/IV 0.250.5 mg/kg q12h (max: 40 mg/d)
Pathological Hypersecretory Conditions
Adult: PO 20160 mg q6h IV 20 mg q6h
Adult: PO 10 mg b.i.d.
Child: PO 1 mg/kg/d in 2 divided doses (max: 40 mg b.i.d.)
Clcr <50 mL/min: 50% of usual dose or usual dose q3648h
- Give with liquid or food of patient's choice; an antacid may also be given if patient is also on antacid therapy.
- Store at 15°30° C (59°86° F). Protect from moisture and strong light; do not freeze.
- Note: Verify correct IV concentration and rate of infusion/injection with physician before administration to infants or children.
PREPARE: Direct: Dilute 20 mg (2 mL) famotidine IV solution (containing 10 mg/mL) with D5W, NS, or other compatible IV diluent (see manufacturer's
directions) to a total volume of 5 or 10 mL. IV Infusion: Dilute 2 mL famotidine IV with 100 mL compatible IV solution.
ADMINISTER: Direct: Give over not less than 2 min. IV Infusion: Infuse over 1530 min.
INCOMPATIBILITIES Y-site: Amphotericin B cholesteryl complex, azithromycin, cefepime, piperacillin/tazobactam.
- Store IV solution at 2°8° C (36°46° F); reconstituted IV solution is stable for 48 h at room
temperature 15°30° C (59°86° F).
Adverse Effects (≥1%)CNS:
Dizziness, headache, confusion, depression
. GI: Constipation
, diarrhea. Skin:
, pruritus, dry skin, flushing. Hematologic:
Increases in BUN and serum creatinine.
May inhibit absorption of itraconazole
Incompletely from GI tract (4050% reaches systemic circulation). Onset:
1 h. Peak:
13 h PO; 0.53 h IV. Duration:
1012 h. Metabolism:
In liver. Elimination:
In urine. Half-Life:
Assessment & Drug Effects
- Monitor for improvement in GI distress.
- Monitor for signs of GI bleeding.
Patient & Family Education
- Be aware that pain relief may not be experienced for several days after starting therapy.